Title | Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease [electronic resource] : A Focus on Early Phase Clinical Drug Development / edited by Andrew J. Krentz, Christian Weyer, Marcus Hompesch |
---|---|
Imprint | Cham : Springer International Publishing : Imprint: Springer, 2019 |
Edition | 2nd ed. 2019 |
Connect to | https://doi.org/10.1007/978-3-030-11748-1 |
Descript | XI, 556 p. 115 illus., 59 illus. in color. online resource |
Part 1: Review of Clinical Investigative Methods -- Chapter 1: Quantifying Insulin Action in Humans -- Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function -- Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins -- Chapter 4: Measurement of Energy Expenditure -- Chapter 5: QUANTIFYING APPETITE AND SATIETY -- Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition -- Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development -- Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes -- Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates -- Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders -- Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH -- Chapter 12: Omics: Potential role in early phase drug development -- Part 2: Preclinical Drug Development and Transitioning to Clinical Studies -- Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases -- Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS – CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT -- Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c -- Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis -- Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview -- Chapter 18: Transitioning from Preclinical to Clinical Drug Development -- Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders -- Chapter 20: Early Phase Metabolic Research with Reference to Special Populations